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BACKGROUND The ABSORB III Pharmacokinetic (PK) study is a pro-
spective, open-label, non-randomized sub-study of the ABSORB III
randomized trial designed to determine the PK of everolimus deliv-
ered by the Absorb bioresorbable vascular scaffold (BVS) in subjects
who only receive Absorb BVS with a maximum treatment of two de
novo coronary artery lesions. The pharmacokinetic proﬁle of Absorb
BVS has not previously been described.
METHODS Twelve subjects were enrolled at two sites in the United
States. Subjects received one (n¼8) or two (n¼4) Absorb BVS with
diameters of 2.5., 3.0 or 3.5 mm and lengths of 8, 12, 18 or 28 mm. The
total everolimus dose received ranged from 181 to 443 mg. Blood
samples (arterial or venous) were collected from the subjects pre-
procedure and at ﬁfteen time points post-procedure (10 and 30 mi-
nutes, 1, 2, 4, 6, 12, 24, 48, 72, 96, 120 (day 5), 168 (day 7), 336 (day 14),
and 720 hours (day 30) after the last scaffold implantation). The
concentration of everolimus in the blood was determined by Liquid
Chromatography-Mass Spectrometry/Mass Spectrometry assay. The
lower limit of quantiﬁcation was 0.1 ng/mL. The blood concentration-
time data were subjected to non-compartmental methods to deter-
mine PK parameters (Cmax, tmax, AUC, t1/2).
RESULTS Everolimus blood concentrations increased rapidly after
Absorb BVS deployment, reaching maximum concentration between
0.17 and 2.37 hours (tmax), declining thereafter with a terminal half-
life ranging between 45.9 and 115 hours. By 4 hours, everolimus blood
concentrations were below 3 ng/ml (the chronic therapeutic level
necessary to prevent organ rejection in transplant patients) in all
subjects. Everolimus blood concentrations were low but measurable
for up to 168 hours (7 days) after last scaffold deployment. The
maximum observed everolimus concentration (Cmax) increased with
dose and ranged from 1.085 to 4.460 ng/ml across the dose range
studied. Similarly, individual AUC (AUC24h: 12.09 to 44.22 ng*h/mL;
AUClast: 25.37 to 104.6 ng*h/mL; AUC0-N: 33.15 to 120.8 ng*h/mL)
increased proportionally with total scaffold dose.
CONCLUSIONS The local arterial delivery of everolimus and systemic
exposure increased proportionally with dose and rapidly declined
thereafter. The everolimus PK proﬁles seen with Absorb BVS are safe,
and are similar to previously reported proﬁles for the cobalt chromium
everolimus-eluting XIENCE stent.
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BACKGROUND The bioresorbable scaffold (BRS) is a novel approach
to treat coronary artery lesions. The mechanical properties of the
polymer-based Absorb scaffold (Abbott Vascular, Santa Clara, Cali-
fornia, USA) have already been compared to those of second-genera-
tion metallic DES. Lately, the novolimus-eluting DESolve (Elixir
Medical Corporation, Sunnyvale, California, USA) gained permission
for clinical use in Europe. We aimed to compare with OCT the acute
performance of the Absorb scaffold vs the DESolve scaffold.METHODS Very ﬁnal post deployment OCT pullbacks of consecutive
patients treated with either Absorb or DESolve were reviewed. The
following parameters were calculated: mean and minimal lumen area
(MLA), residual in-scaffold area stenosis (RAS), incomplete strut
apposition (ISA), tissue prolapse area, eccentricity index, symmetry
index, strut fracture and edge dissection.
RESULTS A total of 72 patients were included. The Absorb group
consisted out of 35 patients treated with 63 Absorb scaffolds, which
were compared to a well-matched group of 37 patients treated with 50
DESolve scaffolds. Baseline characteristics did not differ signiﬁcantly
between the two groups. Procedural characteristics were different
with respect to maximal balloon inﬂation pressure (Absorb vs DES-
olve: 21.50.4atm vs 16.83.8atm; p<0.01) and mean NC balloon
diameter used for post-dilatation (Absorb vs DESolve 3.30.4mm vs
3.50.4mm; p<0.01). OCT analysis showed similar MLA (Absorb vs
DESolve: 5.81.9 mm2 vs 6.12.6 mm2; p¼0.43) and mean luminal
area (Absorb vs DESolve: 7.12.2 mm2 vs 7.21.9 mm2 ; 0.77). The
DESolve group showed a larger maximum scaffold diameter (Absorb
vs DESolve: 3.20.5mm vs 3.50.4mm, p¼0.01), a higher minimal
scaffold diameter (2.70.4mm vs 2.90.4mm; p<0.01) with a lower
degree of RAS (Absorb vs DESolve: 20  7.4% vs 14.910.8%, p¼0.16).
The mean eccentricity index was 0.85 0.05 with Absorb and 0.80
0.05 with DESolve, p<0.01. A lower frequency of distal edge ISA
(Absorb vs DESolve: n¼5 [8.2%] vs 16 [32.0%]; p<0.01) and smaller
prolapse area (Absorb vs DESolve : 1.01.1mm2 vs 3.66.2; p<0.01)
was found with Absorb.
CONCLUSIONS The two scaffolds showed similar MLA while there
was a trend toward a lower RAS and a larger maximum and minimum
scaffold diameter with DESsolve. DESolve scaffold was more eccentric
as compared to Absorb. These results might be related to the DESolve
peculiar expansion properties.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bioabsorbable, Bioabsorbable scaffolds
TCT-515
Multi-Center, Post-marketing Evaluation of the Elixir DESolve Novolimus
Eluting Bioresorbable Coronary Stent System: 6-month Results from the
DESolve PMCF Study
Holger Nef,1 Karl-Eugen Hauptmann,2 Azeem Latib,3 Ricardo A. Costa,4
Lynn Morrison,5 Sara Toyloy,5 Lynn Vandertie,6 Antonio Colombo7
1Justus-Liebig University of Giessen, Giessen, Germany; 2Krankenhaus
der Barmherzigen Brüder Trier, Trier, Germany; 3Ospedale San
Raffaele, Milan, Italy; 4Instituto Dante Pazzanese de Cardiologia, Sao
Paulo, Brazil; 5Elixir Medical Corporation, Sunnyvale, CA; 6Medical
Device Consultancies, Christ Church, New Zealand; 7EMO GVM Centro
Cuore Columbus/San Raffaele Hospital, Milan, Italy
BACKGROUND A post marketing clinical follow-up study was con-
ducted evaluating the continued safety and effectiveness of the CE-
mark approved DESolve Novolimus Eluting Bioresorbable Coronary
Scaffold System (NEBCSS) (Elixir Medical, Sunnyvale, CA), a drug-
eluting bioresorbable scaffold combining a PLLA-based scaffold
coated with a biodegradable polylactide-based polymer and Novoli-
mus, a macrocyclic lactone mTOR inhibitor. The drug dose is 5 mg
per mm of scaffold length and the device is available in multiple di-
ameters (2.5, 3.0, 3.25 and 3.5) and lengths (14, 18 and 28 mm).
METHODS A total of 100 patients were treated with the DESolve
NEBCSS in de novo lesion coronary artery lesions with a reference
vessel diameter between 2.25 and 3.5 mm and treatable with a single
scaffold between 14 and 28 mm in length. Patient data for the clinical
endpoints of major adverse cardiac events (MACE) deﬁned as: cardiac
death, target vessel MI, clinically-indicated target lesion revasculari-
zation (TLR); target vessel revascularization and stent thrombosis are
to be analyzed at 1, 6, 12 months and annually through 5 years. The
study was approved the local Ethics Committees and all patients
provided informed consent.
RESULTS Patients were enrolled over a one year period at 10 sites in
Germany, and Italy. After the index procedure, patients were con-
tacted at 30 days and 6 months either via an ofﬁce visit or telephon-
ically. Patient demographic, lesion characteristics and clinical results
though 6 months will be presented.
CONCLUSIONS The DESolve NECSS post-marketing clinical follow-up
study demographics and lesion characteristics overview and clinical
results through 6 months will be presented.
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